Literature DB >> 16185925

Activation of peroxisome proliferator-activated receptor-alpha and -gamma in auricular tissue from heart failure patients.

Dulcenombre Gómez-Garre1, Marta Herraíz, Ma Luisa González-Rubio, Rosa Bernal, Paloma Aragoncillo, Amparo Carbonell, Juan José Rufilanchas, Arturo Fernández-Cruz.   

Abstract

OBJECTIVE: Peroxisome proliferator-activated receptors (PPARs), key transcriptional regulators of lipid and energy metabolism in cardiomyocytes, have recently been proposed to modulate cardiovascular pathophysiological responses in experimental models. However, there is little information about the functional activity of PPARs in human heart failure. AIMS: To investigate PPAR-alpha and -gamma expression and activity, and the association with ET-1 production and fibrosis, in cardiac biopsies from patients with end-stage heart failure due to ischemic cardiomyopathy (ICM) in comparison and from non-failing donor hearts. All samples were obtained during cardiac transplantation. METHODS AND
RESULTS: Morphological analysis (by Masson trichrome and image analysis) did not detect fibrosis in the left atrium from non-failing donors (NFLA) or from ICM patients (FLA). However, left ventricles from failing hearts (FLV) contained a greater number of fibrotic areas (NFLA: 3.21+/-1.15, FLA: 1.63+/-0.83, FLV: 14.5+/-3.45%; n = 9, P<0.05). By RT-PCR, preproET-1 expression was similar in the non-failing and failing atrium but was significantly higher in the ventricles from failing hearts (NFLA: 1.00+/-0.06, FLA: 1.08+/-0.11, FLV: 1.74+/-0.19; n = 9, P<0.05). PPAR-alpha and PPAP-gamma mRNA (by RT-PCR) and protein (by Western blot) levels were higher in the ventricles from failing hearts compared with the atrium from failing and non-failing hearts. Electrophoretic mobility shift assays showed that PPAR-alpha and PPAP-gamma were not activated in the ventricles (NFLA: 1.00+/-0.11, FLA: 1.89+/-0.24, FLV: 0.95+/-0.07; n = 9, P<0.05).
CONCLUSIONS: These data suggest that PPAR-alpha and PPAP-gamma are selectively activated in the atria from ICM patients and might be functionally important in the maintenance of atrial morphology.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16185925     DOI: 10.1016/j.ejheart.2005.06.002

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  6 in total

Review 1.  The pathological roles of environmental and redox stresses in cardiovascular diseases.

Authors:  Sahoko Ichihara
Journal:  Environ Health Prev Med       Date:  2012-12-29       Impact factor: 3.674

2.  Mice with cardiac overexpression of peroxisome proliferator-activated receptor γ have impaired repolarization and spontaneous fatal ventricular arrhythmias.

Authors:  John P Morrow; Alexander Katchman; Ni-Huiping Son; Chad M Trent; Raffay Khan; Takayuki Shiomi; Haiyan Huang; Vaibhav Amin; Joshua M Lader; Carolina Vasquez; Gregory E Morley; Jeanine D'Armiento; Shunichi Homma; Ira J Goldberg; Steven O Marx
Journal:  Circulation       Date:  2011-11-28       Impact factor: 29.690

3.  Bilobetin ameliorates insulin resistance by PKA-mediated phosphorylation of PPARα in rats fed a high-fat diet.

Authors:  Xin-Hui Kou; Mei-Feng Zhu; Dai Chen; Yi Lu; Hui-Zhu Song; Jian-Lin Ye; Lin-Feng Yue
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

4.  PPAR-gamma expression in animals subjected to volume overload and chronic Urotensin II administration.

Authors:  Gregory S Harris; Robert M Lust; Jonathan H DeAntonio; Laxmansa C Katwa
Journal:  Peptides       Date:  2008-03-12       Impact factor: 3.750

5.  Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect.

Authors:  D Gómez-Garre; P Muñoz-Pacheco; M L González-Rubio; P Aragoncillo; R Granados; A Fernández-Cruz
Journal:  Br J Pharmacol       Date:  2009-02-16       Impact factor: 8.739

Review 6.  Peroxisome Proliferator-Activated Receptor-γ Is Critical to Cardiac Fibrosis.

Authors:  Huang-Jun Liu; Hai-Han Liao; Zheng Yang; Qi-Zhu Tang
Journal:  PPAR Res       Date:  2016-05-12       Impact factor: 4.964

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.